Taiwan sits, along with its smaller counterparts, Singapore and Hong Kong, as one of the gateway countries to running a clinical trial in China. Although Hong Kong’s regulatory ties are more formalized with China, than Taiwan, Taiwan has the right environment and population to make the possibility of greater regulatory cohesion with its giant neighbour, […]
Read More
Generally, the unit of randomization in a randomized clinical trial (RCT) is the individual participant (the patient). Occasionally, the unit of randomization can be a cluster, such as hospitals, schools, villages, etc. When randomizing large groups, the concept of cluster randomized trials (CRTs) has become increasingly common. Patient clusters are allocated to the intervention arms […]
Read More
On the heels of our recent post on our presence at this week’s DIA Japan 2015, BBK welcomes Philip Gregory, the General Manager of George Clinical – CRO China as our guest contributor. With more than 20 years of experience in pharmaceutical, biotech and medical device marketing, Mr. Gregory has spent over 14 years supporting the […]
Read More
George Clinical East Asia is headquartered in Hong Kong. From this location, we oversee our on the ground operations in Hong Kong, Taiwan and Malaysia; whilst enabling coverage of other South East Asian countries such as Singapore and Philippines. Office Locations: Units 4305-06, Tower 1, Metroplaza, 233 Hing Fong Road, Kwai Fong, New Territories […]
Read More
In order to meet the growing needs of our customers, George Clinical has expanded its geographical footprint within Asia. In 2012 we saw the opening of a second George Clinical office in India in Bengaluru to complement our head office in Hyderabad. With many of our large outcomes studies recruiting patients in India there is […]
Read More
